Vascular Endothelial Factor Gene Polymorphism in Preeclampsia

Completed

• Conditions: Preeclampsia
• Interventions: Diagnostic Test: PCR; Device: Doppler ultrasound

• Registration Number: NCT03500588
• Lead Sponsor: Beni-Suef University

Brief Summary

In this study, the investigators assessed one of the released protein factors during the pathophysiology of preeclampsia. They evaluated vascular endothelial growth factor gene mutation which affects the angiogenesis in case of inadequate placentation and its association with Doppler changes in the pulsatility index of the umbilical artery.

Detailed Description

Preeclampsia is a syndrome characterized by occurrence of hypertension and proteinuria after 20 weeks of gestation. The pathophysiology of preeclampsia involves abnormalities in the development of placental vasculature early in pregnancy may result in relative placental under perfusion/hypoxia/ischemia, which then leads to release of factors into the maternal circulation that alter maternal endothelial function and cause hypertension and other manifestations of disease .Vascular endothelial growth factor (VEGF) is a signal protein produced by cells that stimulates vasculogenesis and angiogenesis. It is part of the system that restores the oxygen supply to tissues when blood circulation is inadequate. Human VEGF gene is located on chromosome 6 and consists of 8 exons with alternate splicing, forming a family of proteins. There are several common single nucleotide polymorphisms (SNPs) in the VEGF gene, which could alter gene expression and protein production, and alter the risk of developing diseases characterized by deranged angiogenesis including preeclampsia.

Study Timeline

• Study Start: 2017-01
• Primary Completion: 2018-01
• Study Completion: 2018-02
• Study First Submitted: 2018-04-10
• Study First Submitted QC: 2018-04-10
• Study First Posted: 2018-04-18
• Status Verified: 2021-03
• Last Update Submitted: 2021-03-24
• Last Update Posted: 2021-03-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 290

Inclusion Criteria

More than 20 weeks gestation. Preeclamptic patients

Exclusion Criteria

association with chronic disease (cardiac, hepatic, renal) and if the patient was known to have chronic hypertension.

association with auto-immune disease.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Pregnant women after 20 weeks with preeclampsia.	PCR	One hundred and forty-five pregnant women after 20 weeks with preeclampsia were evaluated for VEGF gene mutation by using PCR and Pulsitality index of umbilical artery by doppler velocimetry.
Pregnant women after 20 weeks with preeclampsia.	Doppler ultrasound	One hundred and forty-five pregnant women after 20 weeks with preeclampsia were evaluated for VEGF gene mutation by using PCR and Pulsitality index of umbilical artery by doppler velocimetry.
normotensive pregnant women more than 20 weeks gestation.	PCR	One hundred and forty-five pregnant women after 20 weeks with normal blood pressure were evaluated for VEGF gene mutation.

Primary Outcome Measures

Name	Time	Method
Correlation of VEGF gene mutation and preeclampsia	from 20 weeks until delivery	Is VEGF gene polymorphism associated with preeclampsia

Secondary Outcome Measures

Name	Time	Method
maternal outcome	from 20 weeks until delivery	Maternal admission to intensive care unit
fetal and neonatal outcomes	from 20 weeks until first postpartum week.	Intrauterine growth restriction

Trial Locations

Locations (1)

Beni-Suef University; 🇪🇬 Cairo, Beni-Suef, Egypt